Results 111 to 120 of about 542,971 (347)

A Validated Model to Predict Severe Weight Loss in Amyotrophic Lateral Sclerosis

open access: yesAnnals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Severe weight loss in amyotrophic lateral sclerosis (ALS) is common, multifactorial, and associated with shortened survival. Using longitudinal weight data from over 6000 patients with ALS across three cohorts, we built an accelerated failure time model to predict the risk of future severe (≥ 10%) weight loss using five single‐timepoint ...
David G. Lester   +4 more
wiley   +1 more source

Early Intensive Versus Escalation Approach: Ten‐Year Impact on Disability in Relapsing Multiple Sclerosis

open access: yesAnnals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Objective To evaluate the long‐term impact of early intensive treatment (EIT) versus escalation (ESC) strategies using high‐efficacy disease‐modifying therapies (HE‐DMTs) on disability progression in relapsing multiple sclerosis (RMS). Methods This observational study included 4878 RMS patients from the Italian Multiple Sclerosis Register ...
Pietro Iaffaldano   +47 more
wiley   +1 more source

A Differential Dosimetry of Pile Radiations Using Fe2+ Oxidation. [PDF]

open access: bronze, 1952
Einar Sæland   +5 more
openalex   +1 more source

Identification of Dementia With Lewy Bodies by Skin Biopsy in Recent‐Onset Cognitive Impairment

open access: yesAnnals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Immunofluorescence for phosphorylated alpha‐synuclein in skin biopsy samples is an emerging biomarker in synucleinopathies comprising Dementia with Lewy bodies. In this pilot study, 19 patients with recent‐onset (≤ 18 months) cognitive impairment underwent skin biopsy at baseline, with follow‐up clinical re‐evaluation.
Alessandro Furia   +13 more
wiley   +1 more source

Durable B‐Cell Impairment While Sparing IgA B Cells After Ocrelizumab Therapy in Multiple Sclerosis

open access: yesAnnals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Objectives Ocrelizumab (OCR), a humanized anti‐CD20 monoclonal antibody, is highly efficient in relapsing–remitting multiple sclerosis (RR‐MS). We assessed early cellular B‐cell profiles in patients prior to OCR treatment, on OCR treatment, and after 15 months of therapy discontinuation.
Alexandra Garcia   +20 more
wiley   +1 more source

The Road Not Taken: Misclassifying an Anti‐Seizure Medication as a Failure

open access: yesAnnals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Objective To quantify how often anti‐seizure medications (ASMs) appear ineffective yet provide benefit when considering seizure frequency (SF) variability. Methods We used the CHOCOLATES seizure diary simulator to generate 100,000 patient seizure diaries that reflect natural SF variation in a heterogeneous population.
Christopher N. Henry   +1 more
wiley   +1 more source

Associations of Stroke With Risk of Epilepsy: Results From the Atherosclerosis Risk in Communities (ARIC) Study

open access: yesAnnals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Objective To estimate the risk of epilepsy associated with stroke in a community‐based cohort, with consideration of stroke type, number, and severity. Methods Data from 15,100 Atherosclerosis Risk in Communities (ARIC) Study participants without stroke at baseline (1987–1989) were analyzed through 12/31/2022.
Jiping Zhou   +11 more
wiley   +1 more source

Assessing the Prognostic Value of 13 Inflammation-Based Scores in Patients with Unresectable or Advanced Biliary Tract Carcinoma After Immunotherapy

open access: yesImmunoTargets and Therapy
Fang Wang,1,* Chang Jiang,2– 4,* Wenzhuo He,2– 4,* Heping Li,1 Gui-Fang Guo,2– 4 Lixia Xu1 1Department of Oncology, The First Affiliated Hospital of Sun Yat-Sen University, Guangzhou, Guangdong Province, People’s Republic of China; 2State Key
Wang F   +5 more
doaj  

Home - About - Disclaimer - Privacy